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Loading capacity and drug leakage from vehicles during circulation in blood is a major 
concern when developing nanoparticle-based cell-targeted cytotoxics. To circumvent 
this potential issue it would be convenient the engineering of drugs as self-delivered 
nanoscale entities, devoid of any heterologous carriers. In this context, we have here 
engineered potent protein toxins, namely segments of the diphtheria toxin and the 
Pseudomonas aeruginosa exotoxin as self-assembling, self-delivered therapeutic 
materials targeted to CXCR4+ cancer stem cells. The systemic administration of both 
nanostructured drugs in a colorectal cancer xenograft mouse model promotes efficient 
and specific local destruction of target tumor tissues and a significant reduction of the 
tumor volume. This observation strongly supports the concept of intrinsically 
functional protein nanoparticles, which having a dual role as drug and carrier, are 





Natural protein toxins are produced by different species of unicellular and pluricellular 
organisms and are extremely potent functional molecules [1]. Toxins occur alone or as 
venom components with roles in predation and defense or during tissue colonization 
in bacterial infections and show a wide spectrum of mechanisms of action that target 
vital physiological processes. The biological properties of protein toxins can be 
exploited in a therapeutic context, because they are usually preserved in versions 
produced by recombinant DNA technologies. This fact allows the industry-oriented, 
large-scale bioproduction and further formulation of protein toxins as medicines. A 
few toxin-based drugs have been already approved for use in humans by the 
medicament agencies, including Captopril for hypertension, Prialt for chronic pain, 
Integrilin for coronary angioplasty, Byetta for type 2 diabetes, Botox for neuromuscular 
disorders and Contulakin-G as an analgesic [2-6]. Many others are currently under 
development or in clinical trials [7-9]. A major therapeutic value of toxins relies on 
their ability to kill exposed cells through molecular events that are devoid, in general, 
of cell type specificity. The high potency exhibited by some toxins enables toxin-
mediated cell killing to be explored in oncology to replace or complement conventional 
chemotherapies [10, 11]. However, not only efficient but selective cell killing should be 
envisaged when developing antitumoral drugs, to minimize the undesired adverse 
effects and potentially severe toxicity associated to conventional chemotherapies. As 
an example, in the drug Denileukin diftitox, cell targeting is provided by the human 
interleukin-2. Fused to the fragments A and B of the Corynebacterium diphtheriae 
exotoxin (diphtheria toxin), this cytokine allows binding of the whole fusion to the IL-2 
receptor, overexpressed in cutaneous T cell lymphoma cells. Ideally, toxins for use in 
oncology should be targeted by highly specific ligands of tumoral surface markers [12-
15] and administered in stable formulations ensuring bioavailability and minimizing 
renal filtration. This would be achieved by presenting them in sizes over the renal 
clearance threshold (~ 8 nm), through the use of nanoscale carriers. Regarding the 
extremely high potency of toxins, possible drug leakage from the vehicle during blood 
circulation represents an important risk that limits the development of toxin-based 
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nanoconjugates. In addition, the intrinsic potential toxicity of the nanoparticle used as 
carrier, is a matter of additional concern at both individual and environmental levels 
[16, 17]. In this regard, the current trends towards developing self-delivery nanoscale 
drugs devoid of heterologous vehicles [18] might potentially expand the fields or 
applicability of toxins and other cytotoxic protein drugs in safer ways. However, the 
first prototypes in this line have resulted in very complex combinations of different 
types of molecules, that devoid of true nanoscale vehicles, require instead the 
assistance of accompanying molecular systems to provide the required functions. For 
instance, self-assembling therapeutic siRNA has been combined with polymeric 
metformin, condensed with hyaluronic acid and the nanoparticles covered with 1,2-
dioleoyl-3-tri-methylammonium-propane chloride and cholesterol and functionalized 
with a sigma receptor ligand [19]. As another recent example, the anticancer agent 
epigallocatechin gallate was induced to self-assemble in combination with the 
antitumoral proteins herceptin or interferon alpha-2a (IFN-a 2a), followed by coating  
with polyethylene glycol [20].   
In contrast to the chemical heterogeneity of these constructs, that are observed as 
representative of vehicle-free nanomedicines [18], the emerging concept of self-
delivered nanoscale drugs could be fully achieved by functional recruitment in single 
molecular species that such as proteins, can oligomerize as chemically homogeneous 
nanoscale entities with predefined properties [21]. Importantly, nanoscale size in drug 
formulations is of high clinical relevance as cell penetrability and drug stability are 
favoured, the enhanced permeability and retention (EPR) effect stimulated and renal 
clearance largely minimized [18, 22]. Recently [23], we have proposed a biological 
principle to promote self-assembling of fusion proteins as stable protein-only 
nanoparticles using cationic end-terminal tags. In addition, we have proved that short 
protein segments, such as pro-apoptotic or antimicrobial peptides, might retain their 
therapeutic potential when fused to carrier proteins such as GFP and once organized in 
oligomers [24]. Then, a protein toxin might be genetically instructed, by the addition of 
architectonic and cell targeting tags, to self-assemble into stable nanoparticles acting 
as intrinsically functional, cell-targeted protein materials with self-delivery properties. 
In this context, we have here engineered two potent toxins as CXCR4-targeted self-
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assembling nanoparticles for the systemic treatment of CXCR4+ colorectal cancer. 
These proteins are the active fragments of the diphtheria toxin and of the 
Pseudomonas aeruginosa exotoxin, that perform ADP-ribosylation of the elongation 
factor 2 (EF-2), resulting in the irreversible inhibition of protein synthesis and cell 
death [25, 26]. In addition, we designed these drug biomaterials to proteolytically 
discharge the targeting agent and other non-relevant protein segments upon cell 
internalization, for the cytotoxic activity being solely executed by the precise protein 




2. Materials and Methods 
2.1 Protein design, production, purification and characterization 
Synthetic genes encoding the self-assembling modular proteins T22-DITOX-H6 and 
T22-PE24-H6 respectively were designed in-house (Figure 1A) and provided by Geneart 
(ThermoFischer). DITOX contains the translocation and catalytic domains of the 
diphtheria toxin from Corynebacterium diphtheriae. PE24 is based in the de-immunized 
catalytic domain of Pseudomonas aeruginosa exotoxin A in which point mutations that 
disrupt B and T cell epitopes have been incorporated. Moreover, it has been added a 
KDEL sequence in the C-terminus of T22-PE24-H6, which enables the binding to KDEL 
receptors more efficiently at the Golgi apparatus during subsequent intracellular 
trafficking [27]. Furin-cleavage sites were inserted between the CXCR4 ligand T22 and 
the functional toxin (Figure 1A) to release the amino terminal peptide once 
internalized into target cells. This has been designed so as the natural version of both 
toxins act with free amino termini [26, 28], and the recombinant versions proved to be 
active also show this terminal end in absence of additional peptide segments [29, 30]. 
Both gene fusions were inserted into the plasmid pET22b, and the recombinant 
versions of the vector were transformed by heat shock in Escherichia coli Origami B 
(BL21, OmpT-, Lon-, TrxB-, Gor-, Novagen, Darmstadt, Germany). Transformed cells 
were grown at 37 ºC overnight in LB medium supplemented with 100 µg/ml ampicillin, 
12.5 µg/ml tetracycline and 15 µg/ml kanamycin. The encoded proteins were 
produced at 20 ºC overnight upon addition of 0.1 and 1 mM IPTG (isopropyl-β-D-
thiogalactopyronaside) for T22-DITOX-H6 and T22-PE24-H6 respectively, when the 
OD550 of the cell culture reached around 0.5-0.7. Bacterial cells were centrifuged 
during 15 min (5,000 g at 4 ºC) and kept at -80 ºC until use. Pellets were thaw and 
resuspended in Wash buffer (20 mM Tris-HCl pH 8.0, 500 mM NaCl, 10 mM imidazole) 
in presence of protease inhibitors (Complete EDTA-Free, Roche Diagnostics, 
Indianapolis, IN, USA). Cell disruption was performed by French Press (Thermo FA-
078A) at 1200 psi. The lysates were then centrifuged for 45 min (15,000 g at 4 ºC), and 
the soluble fraction was filtered using a pore diameter of 0.2 µm.  
Proteins were then purified through the His-tag by Immobilized Metal Affinity 
Chromatography (IMAC) using a HiTrap Chelating HP 1 ml column (GE Healthcare, 
Piscataway, NJ, USA) with an AKTA purifier FPLC (GE Healthcare). Elution was achieved 
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using a lineal gradient of Elution buffer (20 mM Tris-HCl pH 8.0, 500 mM NaCl and 500 
mM imidazole). The eluted fractions were collected, dialyzed against carbonate buffer 
(166 mM NaCO3H pH 8) and centrifuged for 15 min (15,000 g at 4 ºC) to remove 
insoluble aggregates. The integrity and purity of the proteins was analyzed by mass 
spectrometry (MALDI-TOF), SDS-PAGE and Western blotting using anti-His monoclonal 
antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Protein concentration was 
determined by Bradford’s assay. The nomenclature used for the fusion proteins has 
been established according to their modular organization.  
 
2.2 Furin cleavage design and detection 
To promote the intracellular release of ligand-free toxins, two different furin cleavage 
sites, naturally acting in the respective toxin precursors to activate translocation, were 
included in T22-DITOX-H6 and T22-PE24-H6 (Figure 1A). Efficiency of cleavage in the 
platform was assessed in T22-DITOX-H6, since the expected fragments should exhibit 
fully distinguishable molecular masses suitable for quantitative analysis. For that, HeLa 
cell extracts exposed to 1 µM protein for 24 h were submitted to a Western Blot 
analysis. After protein incubation, cells were collected, centrifuged, suspended in DPBS 
and disrupted by sonication. The Western Blot bands were quantified using Image Lab 
Software version 5.2.1. Two additional modular proteins were also constructed in 
which these engineered furin cleavage sites were not included, namely T22-DITOX-H6 
F- and T22-PE24-H6 F-. Their amino acid sequence exactly matched that of the 
equivalent constructs T22-DITOX-H6 and T22-PE24-H6 at exception of the boldface 
dark blue peptide (Figure 1 A), corresponding to the protease target site. These non-
cleavable constructs were used for a comparative analysis of protein cytotoxicity. 
 
2.3 Fluorescence labelling and dynamic light scattering  
T22-DITOX-H6 and T22-PE24-H6 were labelled with ATTO 488 (Sigma Aldrich, Buchs, 
Switzerland) to track their internalization when performing in vitro and in vivo 
experiments. The conjugation was performed at a molar ratio of 1:2 at room 
temperature in darkness. The reaction mixture was gently stirred every 15 min during 
1 h, centrifuged for 15 min (15,000 g at 4 ºC) and dialyzed overnight in the original 
buffer (166 mM NaCO3H pH 8) to eliminate free ATTO. Fluorescence of the 
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nanoparticles at 0.1 mg/ml was determined by a Varian Cary Eclipse fluorescence 
spectrophotometer (Agilent Technologies, Mulgrave, Australia) at 523 nm using an 
excitation wavelength of 488 nm. For comparative analyses, the intensity of 
fluorescence was corrected by protein amounts to render specific emission values. 
Stability of dye conjugation was assessed through the incubation of T22-DITOX-H6* at 
a final concentration of 0.5 μg/μL in human serum (S2257-5ML, Sigma, St Louis, MO, 
USA) for 48 h at 37 °C, with gentle agitation. Then, the sample was dialyzed in 300 ml 
of carbonate buffer (166 mM NaCO3H, pH 8) for 2 h to remove the free ATTO that 
might have been released from the nanoparticle. In parallel a positive control was 
dialyzed containing the same amount of free ATTO. The fluorescence of buffers 
obtained after the dialysis was measured in the fluorimeter. The volume size 
distribution of all nanoparticles was determined by dynamic light scattering (DLS) at 
633 nm (Zetasizer Nano ZS, Malvern Instruments Limited, Malvern, Worcestershire, 
UK). 
 
2.4 Ultrastructural characterization  
Size and shape of T22-DITOX-H6 and T22-PE24-H6 nanoparticles at nearly native state 
were evaluated with a field emission scanning electron microscope (FESEM) Zeiss 
Merlin (Zeiss, Oberkochen, Germany) operating at 1 kV. Drops of 3 µl of each protein 
sample were directly deposited on silicon wafers (Ted Pella Inc., Reading, CA, USA) for 
1 min, excess blotted with Whatman filter paper number 1 (GE Healthcare, Piscataway, 
NJ, USA), air dried, and observed without coating with a high resolution in-lens 
secondary electron detector. For each sample, representative images of different fields 
were captured at (magnifications (from 120,000x to 200,000x). 
 
2.5 Cell culture and flow cytometry  
CXCR4+ cervical, colorectal and pancreatic cancer cell lines were used to study the 
performance of the recombinant proteins in vitro (HeLa ATCC-CCL-2, SW1417 ATCC-
CCL-238 and Panc-1 ATCC-CCL-1469). HeLa cells were maintained in Eagle's Minimum 
Essential Medium (Gibco®, Rockville, MD, USA), whereas SW1417 and Panc-1 in 
Dulbecco's Modified Eagle's Medium (Gibco®). All of them were supplemented with 10 
9 
 
% foetal bovine serum (Gibco®) and incubated in a humidified atmosphere at 37 ºC 
and 5 % of CO2 (at 10 % for SW1417 cells).  
 
In order to monitor protein internalization, HeLa cells were cultured on 24-well plates 
at 3·104 cells/well for 24 h until reaching 70 % confluence. Proteins were incubated for 
1 h at different concentrations (100, 500 and 1,000 nM) in presence of OptiPRO™ SFM 
supplemented with L-glutamine. Additionally, specific internalization through CXCR4 
receptor was proved adding a specific antagonist, AMD3100 [31, 32], which is 
expected to inhibit the interaction with T22. This chemical inhibitor was added 1 h 
prior protein incubation at a ratio of 1:10. Furthermore, kinetics of the internalization 
was performed at a concentration of 1 µM, after different periods of incubation (0, 20, 
30, 60, 120, and 240 min). After protein exposure, cells were detached using 1 mg/ml 
Trypsin-EDTA (Gibco®) for 15 min at 37 ºC, a harsh protocol designed to remove 
externally attached protein [33]. The obtained samples were analyzed by a FACS-Canto 
system (Becton Dickinson, Franklin Lakes, NJ, USA) using a 15 mW air-cooled argon ion 
laser at 488 nm excitation. Experiments were performed in duplicate. 
 
2.6 Confocal laser scanning microscopy 
For confocal microscopy HeLa cells were grown on Mat-Tek plates (MatTek 
Corporation, Ashland, MA, USA). Upon exposure to the materials cell nuclei were 
labelled with 5 μg/ml Hoechst 33342 (ThermoFischer, Waltham, MA, USA) and the 
plasma membrane with 2.5 μg/ml CellMaskTM Deep Red (ThermoFischer) for 10 min at 
room temperature. Cells were then washed in PBS buffer (Sigma-Aldrich, Steinheim, 
Germany). The confocal images of the HeLa cells were collected on an inverted TCS SP5 
Leica Spectral confocal microscope (Leica Microsystems, Wetzlar, Germany) using 63x 
(1.4 NA) oil immersion objective lenses. Excitation was reached via a 405 nm blue 
diode laser (nucleic acids), 488 nm line of an argon ion laser (nanoparticles) and 633 
nm line of a HeNe laser (Cell membrane). Optimized emission detection bandwidths 
were configured to avoid inter-channel crosstalk and multitrack sequential acquisition 
setting were used. The confocal pinhole was set to 1 Airy unit and z-stacks acquisition 
intervals were selected to satisfy Nyquist sampling criteria. Three-dimensional images 
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were processed using the Surpass Module in Imaris X64 v.7.2.1. software (Bitplane, 
Zürich, Switzerland). 
 
2.7 Cell viability assays  
The CellTiter-Glo® Luminescent Cell Viability Assay (Promega, Madison, WI, USA) was 
used to determine the cytotoxicity of T22-DITOX-H6, T22-PE24-H6, T22-DITOX-H6 F- 
and T22-PE24-H6 F- nanoparticles on HeLa, SW1417 CXCR4+ or SW1417 CXCR4- cell 
lines. Cells were cultured in opaque-walled 96-well plates at 3,500 or 6,000 cells/well 
during 24 h at 37 ºC until reaching 70 % confluence. All protein incubations were 
performed in the corresponding medium according to the cell line used. Inhibition of 
cell death was analysed by adding AMD3100, a chemical antagonist of CXCR4 [34, 35], 
at a ratio of 1:10, 1 h prior to protein incubation. T22-GFP-H6, a non-functional T22-
bearing protein [36] was also used as a competitor of T22-empowered toxins at a final 
concentration of 2 µM. After protein incubation, a single reagent provided by the 
manufacturer was added to cultured cells, which prompted lysis and generated a 
luminescent signal proportional to the amount of ATP present in the sample. The ATP 
generated is directly related to the quantity of living cells that remain in the well. Then, 
plates were measured in a conventional luminometer, Victor3 (Perkin Elmer, Waltham, 
MA, USA). Viability of Panc-1 cells, that overexpress luciferase, was determined with 
an alternative non fluorescence kit (EZ4U) under the same experimental conditions. 
The cell viability experiments were performed in triplicate. 
 
2.8 Biodistribution, pharmacokinetics and apoptotic induction analyses in CXCR4+ 
colorectal cancer mouse model after single dose administration of nanoparticles 
All in vivo experiments were approved by the institutional animal Ethics Committee of 
Hospital Sant Pau. We used 5 week-old female Swiss Nu/Nu mice, weighing 18-20 g 
(Charles River, L’Abresle, France), maintained in specific pathogen-free conditions. To 
generate the subcutaneous (SC) mouse model, we implanted subcutaneously 10 mg of 
the patient-derived M5 colorectal (CCR) tumor tissue from donor animals in the mouse 
subcutis. At day 15, when tumors reached approximately 500 mm3, mice received 50 
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μg single i.v. bolus of T22-DITOX-H6* (n = 3) or 300 μg single i.v. bolus of T22-PE24-H6* 
(n = 3) in NaCO3H.NaCl, pH=8 buffer. Control animals received the same buffer (n = 3) 
or 0.25 µg of free ATTO 488 (n=2). At 5, 24 and 48 h mice were euthanized and 
subcutaneous tumors and organs (brain, lung, liver, kidney and heart) were collected. 
Biodistribution of ATTO-labelled nanoparticles in tumor and non-tumor organs was 
determined by measuring the emitted fluorescence in ex vivo tissue sections (3 mm 
thick) using the IVIS® Spectrum (Perkin Elmer, Santa Clara, CA, USA) platform. The 
fluorescent signal (FLI), which correlates to the amount of administered protein 
accumulated in each tissue, was first digitalized, displayed as a pseudocolor overlay, 
and expressed as radiant efficiency [(p/sec/cm2/sr)/µW/cm2]. The FLI values were 
calculated subtracting FLI signal from experimental mice by FLI auto-fluorescence of 
control mice. Samples were first fixed with 4 % formaldehyde in PBS for 24 h to be 
embedded in paraffin for histopathological evaluation and apoptotic index analyses.  
Pharmacokinetic analyses were performed after a 300 µg single i.v. bolus 
administration of T22-PE24-H6* in 12 Swiss nude mice, or after a 50 µg single bolus 
administration of T22-DITOX-H6* also in 12 animals. We sacrificed three mice per each 
time point, at 0, 1, 2, 5, 24 and 48 h after the administration and obtained 
approximately 1 ml of blood EDTA anticoagulated collection tubes. We measured the 
exact volume of plasma obtained and the fluorescent emission at each time point, and 
calculated the concentration of nanoparticle as referred to the fluorescence emitted 
and concentration of the administered dose.  
Apoptotic induction analyses were performed in 4 μm sections of tumors and normal 
organs (liver, lung, spleen, heart, kidney and brain) stained with hematoxylin and eosin 
(H&E), which were histopathologically analyzed by two independent observers. 
Apoptotic induction was evaluated by both, the presence of cell death bodies in H&E 
stained and Hoechst stained tumor slices.  Triton X-100 (0.5 %) permeabilized sections 
were then stained with Hoechst 33258 (Sigma-Aldrich) diluted, 1:5,000 in PBS, for 1 h, 
rinsed with water, mounted and analyzed under fluorescence microscope (λex=334 
nm/λem=465 nm). The number of apoptotic cell bodies was quantified by recording 
the number of condensed and/or defragmented nuclei per 10 high-power fields 
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(magnification 400x), in blinded samples evaluated by two independent researchers, 
using Cell∧B s  
2.9. Antitumor effect in a CXCR4+ CRC model after nanoparticle repeated dose 
administration 
To generate the CXCR4+ colorectal xenograft mouse models, we used the patient-
derived M5 colorectal tumor tissue. Ten mg fragments obtained from donor animals 
were implanted in the subcutis of Swiss nu/nu mice to generate subcutaneous (SC) 
tumors as described above (n=9). Once tumors reached approximately 120 mm3, mice 
were randomized in Control, T22-PE24-H6 and T22-DITOX-H6 groups and received 
intravenous doses of T22-PE24-H6 or T22-DITOX-H6, both at a repeated dose regime of 
10 µg, 3 times a week, per 8 doses. The control group received buffer using the same 
administration schedule. Mouse body weight was registered over the experimental 
period 3 times a week. Seventeen days after the initiation of nanoparticle 
administration, mice were euthanized and the subcutaneous tumors were taken to 
measure their final tumor volume and to count the number of apoptotic figures in 5 
high-power fields (magnification 400x), of H&E stained tumor sections as described 
above.  
2.10 Statistical analysis   
The specificity of nanoparticle-promoted cell death and the pairwise data comparisons 
were checked with a one-way ANOVA and Tukey’s tests, respectively. Pairwise 
divergences of internalization and cell death were evaluated using Student’s t tests, 
whereas Mann–Whitney U tests were used to pairwise comparisons of the number of 
apoptotic bodies. Differences between groups were considered significant at p< 0.05 
and differences between relevant data are indicated by letters or as ¥ for 0.01 <p< 
0.05 and § for p< 0.01 in the Figures. All statistical analyses were performed using SPSS 
version 11.0 package (IBM, NY, USA), and values were expressed as mean ± standard 
error of the mean (SEM).  
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3 Results  
Active fragments of the diphtheria toxin (DITOX) and the Pseudomonas aeruginosa 
exotoxin (PE24) were produced in Escherichia coli as the modular fusion proteins T22-
DITOX-H6 and T22-PE24-H6 (Figure 1 A, B), intended to induce targeted cell death 
through the activity of the catalytic fragments of the protein drug (Figure 1C). The 
cationic peptide T22, placed at the amino terminus of the whole construct and 
cooperating with carboxy terminal histidines, promotes both oligomerization into 
regular nanoparticles [37] and binding to the cell-surface chemokine receptor CXCR4 
(overexpressed in many aggressive human cancers [38-41]). In this way, it has been 
proved efficient in endorsing the endosomal penetration of payload GFP and IRFP into 
CXCR4+ cancer stem cells [23]. Then, T22-DITOX-H6 spontaneously self-assembled into 
38 and 90 nm-nanoparticles (Pdi= 0.25±0.01 nm) and T22-PE24-H6 into ~60 nm-
nanoparticles (Pdi= 0.22±0.01, Figure 2A), always within the size range considered as 
optimal for efficient cell uptake [22, 42, 43]. A secondary population of protein 
material was observed in the case of T22-PE24-H6, being always minority. 
Nanoparticles were effectively disassembled by 0.1 % SDS, resulting in monodisperse 
building blocks peaking at ~6 nm (Pdi= 0.60±0.01 and 0.30±0.07 respectively), 
compatible with the expected size of the monomeric protein. However, both protein 
nanoparticles were fully stable in several physiological buffers in medium term 
incubation and also when exposed to high salt content buffer (up to 1 M NaCl, not 
shown), what prompted us expecting high stability in vivo. In addition, nanoparticles 
were found stable after one-year storage at -80ºC and upon repeated cycles of 
freezing and thawing (not shown). The assembled proteins appeared as toroid 
materials (Figure 2B), with ultrastructural morphometry (round shape and clear size 
populations) that confirmed the size range observed by DLS. The same regular 
architecture had been previously described for the related T22-GFP-H6 construct, in 
which the GFP-based sub-units (with a molecular size similar to that of T22-DITOX-H6 
and T22-PE24-H6) organized in toroid entities, whose organization has been modelled 
in silico [44] and confirmed by sophisticated analytical methods such as SAXS or high 




Figure 1. A. Native structure of A-B toxins such as diphtheria toxin (Corynebacterium 
diphtheriae) or exotoxin A (Pseudomonas aeruginosa). The native toxin is divided in 
two fragments (A and B). Fragment A includes the catalytic domain (C-domain), 
whereas the fragment B comprises the translocation and the receptor binding domain 
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(T- and R-domain). The selected domains for the construction of the recombinant 
nanoparticles are coloured in dark purple (T22-PE24-H6 construct does not include the 
T-domain). B. Modular organization of T22-DITOX-H6 and T22-PE24-H6, in which T22 
acts as both CXCR4 ligand and as an architectonic tag. Functional segments are 
intersected by linker regions (light blue) and furin-cleavage sites (dark blue, boldface). 
A natural furin-cleavage site also occurs within DITOX (dark blue, underlined), that 
separates the amino terminal catalytic domain from the carboxy terminal translocation 
domain. A KDEL peptide has been incorporated neighboring the H6 region in T22-PE24-
H6. Box sizes are only indicative. Two additional proteins, namely T22-DITOX-H6 F- and 
T22-PE24-H6 F- were constructed for comparative purposes, precisely lacking the 
engineered furin cleavage sites (boldface dark blue regions). C. Expected pathway for 
the cytotoxicity of T22-DITOX-H6 and T22-PE24-H6 nanoparticles over CXCR4+ target 
cells, upon intracellular furin-mediated release of protein domains useful for 
biodistribution and cell penetration steps but irrelevant for cell killing. 
  
  
Figure 2. Nanoarchitecture of toxin-based proteins. A. Size and SDS-mediated 
disassembling of T22-DITOX-H6 and T22-PE24-H6 nanoparticles determined by DLS. 
Values of peak sizes (mode) are indicated in bold (in nm, ± SEM). Z-potential (Zp) 
values of the nanoparticles are also indicated. The molecular mass of proteins upon 
purification is shown by Western Blot upon PAGE-SDS. B. FESEM examination of 
purified T22-DITOX-H6 and T22-PE24-H6 materials. Bars indicate 50 nm. 
 
Purified T22-DITOX-H6 and T22-PE24-H6 nanoparticles were tested for internalization 
into cultured CXCR4+ cells, upon chemically labelling with the fluorescent dye ATTO 
488 (tagged with *, Figure 3A). Both kinds of labelled nanoparticles (Figure 3A) 
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penetrated target HeLa cells in a dose-dependent manner (Figure 3B) and accumulated 
intracellularly with a kinetics characteristic of receptor-mediated uptake (with a faster 
slope in the case of T22-PE24-H6*, Figure 3C). The CXCR4 specificity of the penetration 
was confirmed through its inhibition by the CXCR4 antagonist AMD3100 [34] (Figure 
3D). Internalized nanoparticles were observed as engulfed into endosomes, especially 
in cytoplasm areas close to the cell membrane, but they tended to be visualized as 
membrane-free entities when approaching the perinuclear regions (Figure 3E), 
suggesting important endosomal escape. No cell-attached extracellular fluorescence 
was observed in any case. 
Once the internalization was assessed, we tested if the furin cleavage sites introduced 
in the constructs to release the toxin segments from the building blocks were active in 
the oligomers. The expected intracellular hydrolysis should enhance the cytotoxic 
properties of the toxin domains, which would then benefit from lower load of 
superfluous protein sequences. For that, we explored the sensitivity of the multiple 
cleavage sites in the construct T22-DITOX-H6 that would offer, upon intracellular 
digestion, fully distinguishable protein fragments. Unlike the extracellular protein that 
appears as one single protein species (Figure 2A and 3A), the His tag immunodetection 
of the cell-engulfed protein showed the protein as digested by different alternative 
sites, matching the molecular weight of the expected products for each furin cleavage 
site. In particular, the release of the T22 peptide through the de novo incorporated 
cleavage site was proved in vivo in cell-internalized protein by the shift from the 48.65 
KDa full-length protein to the 44.21 KDa fragment, analyzing cell extracts upon 
exposure to the nanoparticles for 24 h (Figure 4A). The rest of fragments corresponded 
to the progressive digestion intermediates that still kept the carboxy terminal tag, by 
which the protein is immunodetected. The natural cleavage at the internal furin site, 
which releases the catalytic domain from the translocation domain, is also proved by 
the occurrence of the major 20.60 KDa segment. Therefore, the catalytic segment 
alone is expected to occur inside the target cells, among other biologically active 




Figure 3. Internalization of toxin-based nanoparticles in CXCR4+ cells. A. Mass 
spectroscopy of pure unlabeled and ATTO-labelled (*) T22-DITOX-H6 and T22-PE24-H6 
proteins. B. Dose-dependent uptake of T22-DITOX-H6* and T22-PE24-H6* 
nanoparticles in CXCR4+ HeLa cells upon 1 h of exposure.  C. Time course kinetics of cell 
internalization of T22-DITOX-H6* and T22-PE24-H6* nanoparticles (1 µM) in CXCR4+ 
HeLa cells. Note the short error bars in the plot. D. Protein (100 nM) uptake inhibition 
by the CXCR4 antagonist AMD3100 (+) upon 1 h of exposure. Significant differences 
between relevant data pairs are indicated as § for p < 0.01. All A, B and C data are 
presented as mean ± SEM (n = 2). E. Confocal microscopy of HeLa cells exposed for 5 h 
to T22-DITOX-H6* and T22-PE24-H6* nanoparticles (1 µM). The Cell Mask membrane 
staining (red) was added together with nanoparticles to observe the endosomal 
membrane. Nanoparticles are visualized in green and nuclear regions in blue. The 
yellow spots indicate merging of red and green signals. In the insets, 3D Imaris 
reconstructions of confocal stacks. Bars indicate 5 µm. 
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When exploring the cytotoxic effects, both T22-DITOX-H6 and T22-PE24-H6 were 
effective in killing cultured HeLa cells, with low IC50 values (0.78 nM and 0.99 nM 
respectively, not shown). The cytotoxic effect was clearly detectable in several CXCR4-
expressing cell lines, including SW1417 CXCR4+ but not in the isogenic SW1417 CXCR4- 
line (Figure 4B, left). Cytotoxicity was mostly abolished by AMD3100 and by the T22-
displaying biologically inner protein T22-GFP-H6 (Figure 4B, right), thus confirming 
again the specificity of the entrance of the nanoparticles, the intracellular nature of 
the nanoparticle-mediated toxicity and the expected CXCR4 receptor mediation in cell 
killing. Besides, it has been observed a reversion effect of T22-DITOX-H6 (90 %) when 
adding chloroquine, which inhibits endosomal acidification (not shown). This fact 
confirms that the mechanism of action is pH-dependent as described above (Figure 1). 
In this context, we also evaluated the relevance of the removal of accessory protein 
segments (mediated by furin) on the cytotoxicity of the nanoparticles. For that, 
versions of T22-DITOX-H6 and T22-PE24-H6 without the engineered cleavage sites 
(labelled as F-) were constructed and tested for biological activity. The comparative 
analyses of HeLa cell death mediated by these proteins revealed a dramatic drop of 
cytotoxicity in T22-DITOX-H6 F- and T22-PE24-H6 F- nanoparticles compared to the 
original materials (Figure 4 C). On the other hand, the differential CXCR4 expression in 
the isogenic SW1417 cells was fully assessed by immunocytochemistry and Western 
blot (Figure 4 D,E). Interestingly, the capacity of T22-DITOX-H6 and T22-PE24-H6 to 
promote cell death was not lost after one-year storage at -80ºC and also upon four 





Figure 4. Specific cytotoxicity of toxin-based nanoparticles in CXCR4+ cells. A. 
Detection of intracellular T22-DITOX-H6 by Western blot analysis of HeLa cell extracts, 
after exposure of the cell cultures to nanoparticles (1 µM protein) for 24 h.  M 
indicates the migration of molecular weight markers. B. Left: Cell death induced by 
T22-DITOX-H6 and T22-PE24-H6 nanoparticles (10 nM) over a SW1417 CXCR4- cell line 
and different CXCR4+ cell lines (including an isogenic, CXCR4+ SW1417 version), 48 h 
after exposure (72 h for SW1417 cell line). Significant differences between relevant 
data pairs are indicated as ¥ 0.01 <p < 0.05 and § p < 0.01. Right: inhibition of HeLa cell 
death (induced by 10 nM of protein nanoparticles) by either the CXCR4 antagonist 
AMD3100 or by 2 µM protein T22-GFP-H6. Significant differences between relevant 
data are indicated as a change in the letter, from “a” to “b”. All the significant results 
were p < 0.01. All data are presented as mean ± SEM (n = 3). C. HeLa cell death 
promoted by T22-DITOX-H6 F- and by T22-PE24-H6 F-, compared to the related T22-
DITOX-H6 and by T22-PE24-H6 respectively. Cells were exposed to 10 nM of each 
protein for 48 h. Data and statistics are as in panel B. D. Immunocytochemistry staining 
showing the lack of CXCR4 expression in the isogenic SW1417 CXCR4- cells as 
compared with the high CXCR4 expression in SW1417 CXCR4+ cells. Bar indicates 50 
µm. E. Differential CXCR4 protein expression in these cells assessed by an 
immunoblotting assay. Glyceraldehyde-3-phosphate dehydrogenase (GADPH) was 
used as protein loading control. 
 
Due to the high CXCR4+ specific cytotoxicity observed in cell culture, we next tested 
the performance of the toxin-based materials in vivo using a CXCR4-linked disease 
model. For that, we explored the biodistribution, antitumor activity and potential side 
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toxicity of both T22-DITOX-H6* and T22-PE24-H6* nanoparticles in a CXCR4 
overexpressing subcutaneous colorectal cancer model. As expected, after a single dose 
i.v. administration the protein materials accumulated in tumor in the studied time 
range (Figure 5). Other organs such as brain, lung or heart were completely free of 
fluorescence. However, significant levels of emission associated to both nanoparticles 
were found in liver and kidney. To discard that significant amounts of ATTO might had 
been released from the nanoparticles during circulation in blood and generate 
artefacts in the biodistribution analysis, we evaluated the stability of the dye in T22-
DITOX-H6* nanoparticles incubated in commercial serum. At 48 h, only a very minor 
fraction of fluorescence was released from nanoparticles (5 %, Supplementary Figure 1 
A). In addition, the administration of free ATTO did not resulted in detectable 
accumulation in tumor (Supplementary Figure 1 B), and the absence of dye signal in 
major organs was indicative of a fast urine secretion (as expected for a small molecule 
of 981 Da). These data fully supported the biodistribution of labelled nanoparticles 
shown in Figure 5.  
The presence of nanoparticles in liver was observed as worthy of a deeper analysis, 
since hepatic occurrence and damage is a severe concern in conventional and 
innovative cancer therapies, even in nanoconjugates or antibody-based drugs that 
show tissue-specific targeting [46-51]. Then, since it would be of crucial interest to 
discriminate between mere occurrence of fluorescence and toxin-induced damage in 
these organs, we comparatively investigated cell damage in tumor, liver and kidney. In 
this regard, we observed a high level of apoptosis induced by both nanoparticles in 
tumoral tissue, what was especially intense in T22-PE24-H6*-treated animals at 48 h 
post administration (Figure 6). In contrast, apoptosis was undetectable in liver or 
kidney (Figure 6), and most of the hepatic tissues were histologically normal except for 
a few and scattered small inflammation foci (Figure 6) that can be attributed to non-
specific extracellular retention of the drug in off-target tissues. This alteration was 
resolved after 72 h returning to normal histology. Probably, the intracellular activation 
of the toxins promoted by the furin-mediated release of accessory peptides (Figure 4) 




Supplementary Figure 1. Robustness of conjugated ATTO in the biodistribution 
analysis. A. ATTO released from T22-DITOX-H6* nanoparticles upon in vitro incubation 
with commercial sera for 48 h at 37 ºC. Data is obtained by analyzing the dialysis buffer 
and it is referred to dialyzed free ATTO (100 %). Data are presented as mean ± SEM, 
n=4. B. Biodistribution of injected free ATTO 5 h after injection. The ATTO sample 
before inoculation is shown at the bottom. Tumor 1 and 2 refer to two different 





To discard that ATTO might have a positive contribution in the cytotoxicity of the 
materials in tumor after single dose administration we checked local apoptosis in 
animals treated with the non-labelled protein versions T22-DITOX-H6 and T22-PE24-
H6. This was done at the times, among those tested, showing the highest potency (24 
and 48 h respectively). As observed, local apoptosis was still present (Figure 6) at 
values even higher than those induced by the labelled protein versions. This result was 
indicative that the observed antitumoral effect was intrinsically associated to the 
protein material. Then, data supported the notion that in spite of the occurrence of 
the protein drug in liver and kidney, this did not translate in a relevant uptake of any of 
the two nanoparticles in the parenchyma of these tissues. Our observations suggest 
that both labelled protein drugs underwent transient circulation through the 
fenestrated hepatic sinusoids and renal glomeruli despite their nanometric size (in 
contrast to other normal tissues) as reported for other nanoparticles [52]. Moreover, 
their lack of toxicity in kidney or liver suggest their inability to internalize into the 
parenchymal cells in these organs because of their negligible CXCR4 expression, in 
comparison for instance to spleen or bone marrow which despite showing low 
nanoparticle accumulation express CXCR4 [53]. This is a finding similar to that reported 
for CXCR4-targeted imaging agents [54]. Then, both T22-DITOX-H6 and T22-PE24-H6 
appear to have a therapeutic index high enough to validate (i) their potential use for 
the treatment of CXCR4+ tumors but more importantly, (ii) the wide applicability of the 
transversal concept supporting the self-assembling self-driving protein drugs based on 






Figure 5. Biodistribution kinetics of T22-DITOX-H6* and T22-PE24-H6* nanoparticles 
in a CXCR4+ colorectal cancer mouse model. Ex vivo fluorescence emitted by 
subcutaneous tumor and relevant organs in buffer-administered (control) and T22-
DITOX-H6*- and T22-PE24-H6*-treated mice at 5, 24, 48 and 72 h after 50 μg or 300 µg 
single dose i.v. administration. Emission scales are shown as radiant efficiency units 




Figure 6.  Local induction of apoptosis in tumor by ATTO-labelled and unlabeled T22-
DITOX-H6 (50 g) and T22-PE24-H6 (300 g) nanoparticles. A. Representative H&E 
staining of subcutaneous tumors showing apoptotic figures (black arrows). No 
significant apoptosis was detected in liver tissue at the studied times. Few and small 
inflammation foci in this organ were observed and are indicated by yellow arrows, 
which were resolved at 72 h, returning to histologically normal parenchyma. Note the 
absence of histological alterations in kidneys. Bar: 50 µm. B. Number of apoptotic cell 
bodies in H&E tumor slices per ten high-power fields (400× magnification) are plotted 
for each nanoparticle. For the experimental times showing higher number of apoptotic 
lesions we also show representative Hoechst staining of subcutaneous tumors in 
animals treated with unlabeled protein versions, at different magnifications. All data 
are presented as mean ± SEM (n = 3). Statistical significance: ap=0.008; bp=0.027; cp= 




In order to evaluate further the therapeutic potential of the engineered toxins and the 
concepts that support the design of toxin-based nanoparticles we also assessed the 
pharmacokinetics in blood mouse samples after a single dose of 50 µg for T22-DITOX-
H6* or 300 µg for T22-PE24-H6*. This was done through registering their fluorescence 
emission at 0, 1, 2, 5, 24 and 48 h after administration.  We observed a biphasic decline 
in plasma concentration from Cmax, with a fast nanoparticle biodistribution limited to 
the plasma compartment for both tested proteins (Vd=3.9 ml T22-PE-H6* and Vd=3.2 
ml for T22-DITOX-H6*). This fast biodistribution was followed by a second and slow 
elimination phase, with a half-life of t1/2 = 30 h for both nanoparticles (Figure 7 A). 
This kinetic behavior is similar to the one we previously reported for pharmacologically 
inactive protein nanoparticles [23], and also similar to that described for antibody-drug 
conjugates or large nanometric size therapeutic proteins, which show a comportment 
similar to the unconjugated antibody [55]. 
In a step further, we assessed the antitumor effect of each nanoparticle in a CXCR4+ 
subcutaneous CRC mouse model after repeated dose administration. After a dosage 
schedule of 10 µg of T22-DITOX-H6, three times a week, per 8 doses, we observed at 
the end of the experiment a 5.8-fold reduction in tumor volume, as compared to 
buffer-treated mice (p=0.05). This was associated with a 3.0-fold increase in 
apoptoptic figures in tumor tissue (p<0.001) (Figure 7 B), with no significant 
differences in body weight between toxin-treated and control groups (Figure 7 C). 
Similarly, and after a dosage schedule in mice of 10 µg of T22-PE24-H6, three times a 
week, per 8 doses, we observed at the end of the experiment a 2.3-fold reduction in 
tumor volume, as compared to buffer-treated mice (p=0.034), associated with a 3.8-
fold increase in the number of apoptotic figures in tumor tissue (p=0.001) (Figure 7 B). 
Again, no significant differences in body weight between experimental and control 




Figure 7. Pharmacokinetics, antitumoral effect and mouse body weight after T22-
DITOX-H6 and T22-PE24-H6 administration. A. Pharmacokinetics of T22-DITOX-H6* 
and T22-PE24-H6* after a 50 μg or 300 μg intravenous bolus administration 
respectively. Fluorescence was recorded in plasma obtained after blood centrifugation 
at time 0, 1, 2, 5, 24 and 48 h (n=3 per time point). B. Antitumor effect of T22-DITOX-
H6 and T22-PE24-H6 measured by the analysis of tumor volume and number of 
apoptotic bodies at the end of the experiment, after repeated dose administration for 
each nanoparticle (10 μg, three times a week, × 8 doses). C. Evolution of mouse body 
weight after the described repeated dose regime for the protein nanoparticles. 




This set of data is in the line of new nanomedical concepts in targeted drug delivery in 
which the drugs itself act, in addition to their therapeutic functionalities, as self-
assembled and self-delivered entities [18]. Conveniently engineered, the protein drugs 
developed here have been successfully produced and purified in bacteria, and self-
organize as toroid nanoparticles of 30-90 nm (Figure 2). In this form, they penetrate 
CXCR4+ target cells (Figure 3) and promote receptor specific cell killing both in vitro 
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(Figure 4) and in vivo (Figure 6), resulting in significant programmed cell death 
induction and in destruction of tumoral tissue after single dose administration (Figure 
6). Moreover, after repeated dose administration the nanostructured toxins increase 
apoptosis in tumor tissue associated with a significant reduction of tumor volume, with 
no alteration of mouse body weight (Figure 7). These data prove the realistic feasibility 
of the application of these nanostructured toxins in a true therapeutic context. In 
comparison with similar approaches to generate self-assembling peptidic drugs (as 
pro-apoptotic and antimicrobial agents) [24, 56], the concept explored here (i) does 
not use supporting irrelevant proteins such as GFP, thus minimizing the amount of bulk 
inactive material in the drug and enhancing nominal productivity in cell factories and 
(ii) allows the releasing of the active proteins in the cell cytoplasm by the controlled 
discharging of accessory protein segments that had been exploited for self-assembling 
of the building blocks and for the biodistribution and cell-targeted internalization of 
the nanoparticles. In this regard, the intrinsic cytotoxicity of the protein drugs is 
dramatically enhanced by the occurrence of the active domain free from siding 
accessory peptides (Figure 4). This is achieved by the appropriate incorporation of 
intracellular cleavage sites in the fusion protein that allow protein activation once in 
the right cell compartment and promotes the cytotoxic activity being executed solely 
by the minimal functional protein domain. As a generic concept, removing the vehicle 
in cell-targeted nanomedicines [18], would replace the otherwise promoted 
nanoconjugate strategies [57] through the design of new generations of chemically 
homogeneous nanoscale drugs. This would not only allow a heavy reduction of 
fabrication costs, but it will also minimize off-target drug effects, smoother regulatory 
constraints to drug approval and reduce the concerns about individual and 
environmental toxicity of inappropriate materials used as carriers.  In this regard, other 
examples of self-assembling, self-delivered drugs are based on the combination of 
different types of molecules to achieve their function. Note the aggregation of VEGF 
siRNA, PolyMet (polymeric metmorfine), polyethylenimine, dicyandiamide, hyaluronic 
acid, DOTAP, cholesterol, DOTAP and a pegylated targeting ligand [19], or of EGCG, 
PEG, and herceptin or interferon α-2a [20] in self-delivered materials (summarized in 
[18]). The exceptional but technologically simple functional recruitment offered by 
proteins in single polypeptide chains [21] allows not only purifying the drug from 
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recombinant cell factories in a single step by fully standardized recombinant DNA 
technologies [9], but globally, it also conduces to the simple design of self-assembling 
nanoparticles that can be easily fabricated in promising endotoxin-free bacterial 




We provide here data that fully supports an emerging ground-breaking concept in 
nanomedicine that is the generation of self-assembled, self-delivered drugs that act in 
absence of any external vehicle [18]. The approach presented here, based on modular 
recombinant proteins, allows the single-step biological production of nanostructured 
protein materials that exhibit intrinsic therapeutic properties and show an appropriate 
cell targeting and biodistribution upon systemic administration. This is linked to a 
specific biological impact (tumor tissue destruction leading to tumor shrinkage) at the 
local level, because of the cell targeting domains included in the nanoparticle. These 
functional stretches, useful for biodistribution and during the delivery process, are self-
removed from the protein nanoparticles once they have reached the target cell 
compartment. Then, the cytotoxic protein domain acts very efficiently free from any 
accessory protein segment. The design of self-organizing, cell-targeted protein drugs at 
the nanoscale level represents a step forward towards chemically homogeneous 
nanomedicines that should allow to full discard additional, potentially deleterious 
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